Skip to main content
. 2021 Feb 3;137:111313. doi: 10.1016/j.biopha.2021.111313

Table 2.

Summary of HIV protease inhibitors against human coronaviruses.

Infectious disease Drug target Drugs Reported mechanism of action Status
2019-nCoV,
MERS-CoV,
ARS-CoV,
HCoV-229E,
HIV, HPV		 3CLpro Lopinavir Inhibits 3CLpro Approved for HIV, in
phase 3 trials of 2019-nCoV (NCT04252274, NCT04251871, NCT04255017, ChiCTR2000029539), in phase 2/3 trials for MERS (NCT02845843)
2019-nCoV,
MERS-CoV		 3CLpro Ritonavir Inhibits 3CLpro Approved for HIV, in phase 3 trials for 2019-nCoV (NCT04251871, NCT04255017, NCT04261270), in phase 2/3 trials for MERS (NCT02845843)
2019-nCoV 3CLpro Darunavir and cobicistat Inhibits 3CLpro Approved for HIV, in phase 3 trials for 2019-nCoV (NCT04252274)
2019-nCoV 3CLpro ASC09 F (HIV protease inhibitor) Inhibits 3CLpro In phase 3 trials for 2019-nCoV in combination with oseltamivir (NCT0426270)